Your browser doesn't support javascript.
loading
Methods to improve the immunogenicity of plasmid DNA vaccines.
Eusébio, Dalinda; Neves, Ana R; Costa, Diana; Biswas, Swati; Alves, Gilberto; Cui, Zhengrong; Sousa, Ângela.
Affiliation
  • Eusébio D; CICS-UBI - Health Science Research Centre, University of Beira Interior, Av. Infante D. Henrique, 6200-506 Covilhã, Portugal.
  • Neves AR; CICS-UBI - Health Science Research Centre, University of Beira Interior, Av. Infante D. Henrique, 6200-506 Covilhã, Portugal.
  • Costa D; CICS-UBI - Health Science Research Centre, University of Beira Interior, Av. Infante D. Henrique, 6200-506 Covilhã, Portugal.
  • Biswas S; Department of Pharmacy, Birla Institute of Technology & Science-Pilani, Hyderabad Campus, Jawahar Nagar, Shameerpet, Hyderabad 500078, Telangana, India.
  • Alves G; CICS-UBI - Health Science Research Centre, University of Beira Interior, Av. Infante D. Henrique, 6200-506 Covilhã, Portugal.
  • Cui Z; The University of Texas at Austin, College of Pharmacy, Division of Molecular Pharmaceutics and Drug Delivery, Austin, TX 78712, USA.
  • Sousa Â; CICS-UBI - Health Science Research Centre, University of Beira Interior, Av. Infante D. Henrique, 6200-506 Covilhã, Portugal. Electronic address: angela@fcsaude.ubi.pt.
Drug Discov Today ; 26(11): 2575-2592, 2021 11.
Article in En | MEDLINE | ID: mdl-34214667
ABSTRACT
DNA vaccines have emerged as innovative approaches that have great potential to overcome the limitations of current conventional vaccines. Plasmid DNA vaccines are often safer than other vaccines because they carry only antigen genetic information, are more stable and easier to produce, and can stimulate both humoral and cellular immune responses. Although the results of ongoing clinical trials are very promising, some limitations compromise the immunogenicity of these vaccines. Thus, this review describes different strategies that can be explored to improve the immunogenicity of plasmid DNA vaccines, including the optimization of the plasmid vector backbone, the use of different methods for vaccine delivery, the use of alternative administration routes and the inclusion of adjuvants. In combination, these improvements could lead to the successful clinical use of plasmid DNA vaccines.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Vaccines, DNA / Immunogenicity, Vaccine / Adjuvants, Vaccine Limits: Humans Language: En Journal: Drug Discov Today Journal subject: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2021 Document type: Article Affiliation country: Portugal

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Vaccines, DNA / Immunogenicity, Vaccine / Adjuvants, Vaccine Limits: Humans Language: En Journal: Drug Discov Today Journal subject: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2021 Document type: Article Affiliation country: Portugal